Cumbo Alexander — SEC insider filings
SEC reporting owner CIK 1685994. 24 insider filings on record with FilingPulse; latest filed 2026-09-25.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2022-06-13 to 2026-09-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 7 filings — 190,859 shares, $1,123,615 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 37.
- Largest priced transaction: sale of 80,258 shares @ $6.44 ($516,613) in Solid Biosciences Inc., filed 2026-02-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | President and CEO, Director | 12 | — | 7 legs · 190,859 sh · $1,123,615 | 25 |
| Verve Therapeutics, Inc. (VERV) | Director | 5 | — | — | 6 |
| Climb Bio, Inc. (CLYM) | Director | 3 | — | — | 3 |
| Vor Biopharma Inc. (VOR) | Director | 2 | — | — | 2 |
| Stoke Therapeutics, Inc. (STOK) | Director | 2 | — | — | 1 |
Insider filings — Cumbo Alexander
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-25 | 4 | Stoke Therapeutics, Inc. (STOK) | Grant/award (A): 39,674 (derivative) @ $0 | EDGAR |
| 2026-09-25 | 3 | Stoke Therapeutics, Inc. (STOK) | Holdings only — no transactions reported | EDGAR |
| 2026-06-12 | 4 | Vor Biopharma Inc. (VOR) | Grant/award (A): 56,345 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Climb Bio, Inc. (CLYM) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Solid Biosciences Inc. (SLDB) | Grant/award (A): 169,401 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Solid Biosciences Inc. (SLDB) | Option exercise (M): 30,031 · Sale (S): 16,644 @ $5.82 · Option exercise (M): 30,031 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Solid Biosciences Inc. (SLDB) | Sale (S): 48,913 @ $6.44 | EDGAR |
| 2026-02-02 | 4 | Solid Biosciences Inc. (SLDB) | Option exercise (M): 169,401 · Option exercise (M): 100,400 · Sale (S): 80,258 @ $6.44 · Option exercise (M): 169,401 (derivative) @ $0 · Grant/award (A): 509,850 (derivative) @ $0 · Grant/award (A): 254,900 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-04 | 4 | Solid Biosciences Inc. (SLDB) | Option exercise (M): 28,612 · Sale (S): 10,808 @ $5.11 · Option exercise (M): 28,612 (derivative) @ $0 | EDGAR |
| 2025-08-18 | 4 | Solid Biosciences Inc. (SLDB) | Grant/award (A): 337,500 (derivative) @ $0 · Grant/award (A): 168,750 (derivative) @ $0 | EDGAR |
| 2025-07-28 | 4 | Verve Therapeutics, Inc. (VERV) | Disposition to issuer (D): 136,139 (derivative) · Disposition to issuer (D): 42,200 (derivative) | EDGAR |
| 2025-07-18 | 4 | Vor Biopharma Inc. (VOR) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 42,200 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Climb Bio, Inc. (CLYM) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Climb Bio, Inc. (CLYM) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Solid Biosciences Inc. (SLDB) | Option exercise (M): 30,031 · Sale (S): 11,365 @ $3.96 · Option exercise (M): 30,031 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Solid Biosciences Inc. (SLDB) | Grant/award (A): 401,600 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | Solid Biosciences Inc. (SLDB) | Option exercise (M): 28,612 · Sale (S): 11,114 @ $5.60 · Option exercise (M): 28,612 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 136,139 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Solid Biosciences Inc. (SLDB) | Grant/award (A): 240,250 (derivative) @ $0 · Grant/award (A): 120,125 (derivative) @ $0 | EDGAR |
| 2023-12-05 | 4 | Solid Biosciences Inc. (SLDB) | Option exercise (M): 28,612 · Sale (S): 11,757 @ $2.77 · Option exercise (M): 28,612 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 26,642 (derivative) @ $0 | EDGAR |
| 2022-12-05 | 4 | Solid Biosciences Inc. (SLDB) | Grant/award (A): 584 · Grant/award (A): 228,900 (derivative) @ $0 · Grant/award (A): 114,449 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2022-05-23 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1685994 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs